| Index | — | P/E | — | EPS (ttm) | -3.55 | Insider Own | 17.47% | Shs Outstand | 51.27M | Perf Week | 1.58% |
| Market Cap | 330.20M | Forward P/E | 6.15 | EPS next Y | 1.05 | Insider Trans | -0.27% | Shs Float | 49.05M | Perf Month | 1.74% |
| Enterprise Value | 772.20M | PEG | — | EPS next Q | — | Short Float | 19.74% | Perf Quarter | -14.93% | ||
| Income | -177.00M | P/S | 0.43 | EPS this Y | -82.46% | Short Ratio | 8.32 | Perf Half Y | -24.59% | ||
| Sales | 770.00M | P/B | 0.97 | EPS next Y | 190.99% | ROA | -15.83% | Short Interest | 9.68M | Perf YTD | -47.90% |
| Book/sh | 6.65 | P/C | 2.36 | EPS next 5Y | 35.77% | ROE | -35.91% | 52W High | 14.06 -54.20% | Perf Year | -49.84% |
| Cash/sh | 2.73 | P/FCF | 3.84 | EPS past 3/5Y | — -30.34% | ROIC | -5.47% | 52W Low | 4.36 47.71% | Perf 3Y | 199.53% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | -12.73% -13.97% | Gross Margin | 49.40% | Volatility | 6.49% 6.01% | Perf 5Y | -87.34% |
| Dividend TTM | — | EV/Sales | 1.00 | EPS Y/Y TTM | -245.32% | Oper. Margin | -7.06% | ATR (14) | 0.39 | Perf 10Y | -77.11% |
| Dividend Ex-Date | — | Quick Ratio | 2.95 | Sales Y/Y TTM | -9.62% | Profit Margin | -22.96% | RSI (14) | 46.70 | Recom | 2.33 |
| Dividend Gr. 3/5Y | — | Current Ratio | 5.42 | EPS Q/Q | -133.96% | SMA20 | -3.97% | Beta | 2.37 | Target Price | 10.00 |
| Payout | 0.00% | Debt/Eq | 1.71 | Sales Q/Q | 65.96% | SMA50 | -0.90% | Rel Volume | 0.75 | Prev Close | 6.81 |
| Employees | 900 | LT Debt/Eq | 1.71 | Earnings | Mar 03 | SMA200 | -19.41% | Avg Volume | 1.25M | Price | 6.44 |
| IPO Date | Nov 15, 2006 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 2.70% — | Net Debt/EBITDA | — | Volume | 944,175 | Change | -5.43% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-10-26 | Reiterated | HC Wainwright & Co. | Buy | $12 → $10 |
| Mar-09-26 | Reiterated | HC Wainwright & Co. | Buy | $12 |
| Mar-07-24 | Upgrade | Benchmark | Hold → Buy | |
| Aug-29-23 | Downgrade | Benchmark | Buy → Hold | |
| Apr-10-23 | Upgrade | Benchmark | Hold → Buy | |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight | |
| Nov-10-22 | Downgrade | Benchmark | Buy → Hold | |
| May-04-22 | Reiterated | Wells Fargo | Equal Weight | |
| Apr-29-22 | Reiterated | Chardan Capital | Buy | |
| Nov-08-21 | Downgrade | Benchmark | Buy → Hold |
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 770 | 743 | 1,044 | 1,049 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 390 | 392 | 668 | 689 | — | — | — | — | — | |
| Gross Profit | 381 | 351 | 375 | 360 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 182 | 187 | 299 | 357 | — | — | — | — | — | |
| Research and Development | 46 | 54 | 71 | 111 | — | — | — | — | — | |
| Other Operating Expense | 206 | -1 | 114 | 618 | — | — | — | — | — | |
| Operating Income | -54 | 110 | -109 | -726 | — | — | — | — | — | |
| Interest Expense | 51 | 59 | 71 | 88 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -40 | 32 | 37 | 83 | — | — | — | — | — | |
| Net Income Before Taxes | -146 | 83 | -143 | -731 | — | — | — | — | — | |
| Income Taxes | 31 | 30 | 48 | 29 | — | — | — | — | — | |
| Consolidated Net Income | -177 | 53 | -191 | -760 | — | — | — | — | — | |
| Net Income From Continuing Operations | -177 | 53 | -191 | -760 | — | — | — | — | — | |
| Net Income | -177 | 53 | -191 | -760 | — | — | — | — | — | |
| EPS (Recurring) | -3.44 | 0.98 | -3.60 | -14.85 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.44 | 0.98 | -3.60 | -14.85 | — | — | — | — | — | |
| EPS (Diluted) | -3.55 | 0.93 | -3.60 | -14.85 | — | — | — | — | — | |
| EBITDA | 0 | 238 | 57 | -43 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | 13.29 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.43 | 0.90 | 0.49 | 0.12 | — | — | — | — | — | |
| Gross Margin | 49.48 | 47.24 | 35.92 | 34.32 | — | — | — | — | — | |
| Operating Margin | -7.01 | 14.80 | -10.44 | -69.21 | — | — | — | — | — | |
| Net Margin | -22.99 | 7.13 | -18.30 | -72.45 | — | — | — | — | — | |
| Shares Outstanding | 52 | 54 | 53 | 51 | — | — | — | — | — | |
| Market Capitalization | 335 | 667 | 507 | 122 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| DeGolyer Donald W | Director | Oct 07 '26 | Sale | 7.09 | 17,800 | 126,202 | 111,921 | Oct 07 |
| Williams Paul Anthony | SVP, Products Business | Oct 01 '26 | Sale | 6.53 | 3,000 | 19,590 | 156,098 | Oct 05 |
| Williams Paul Anthony | SVP, Products Business | Jul 01 '26 | Sale | 8.40 | 3,000 | 25,200 | 159,098 | Jul 02 |
| Dayal Sujata Tyagi | Director | May 01 '26 | Sale | 8.40 | 13,761 | 115,610 | 100,563 | May 04 |
| DeGolyer Donald W | Director | May 01 '26 | Sale | 8.40 | 15,481 | 129,994 | 129,721 | May 04 |
| Zoon Kathryn C | Director | May 01 '26 | Sale | 8.40 | 17,202 | 144,453 | 79,941 | May 04 |
| Katkin Keith | Director | Apr 30 '26 | Sale | 8.28 | 15,481 | 128,183 | 96,294 | May 04 |
| Williams Paul Anthony | SVP, Products Business | Apr 01 '26 | Sale | 8.44 | 4,000 | 33,760 | 62,681 | Apr 03 |
| Richard Ronald | Director | Dec 05 '25 | Option Exercise | 5.02 | 25,748 | 129,255 | 124,165 | Dec 09 |
| Richard Ronald | Director | Dec 05 '25 | Sale | 11.97 | 21,984 | 263,077 | 98,417 | Dec 09 |
| DeGolyer Donald W | Director | Nov 10 '25 | Sale | 10.54 | 17,801 | 187,623 | 119,858 | Nov 12 |
| Dayal Sujata Tyagi | Director | Nov 07 '25 | Sale | 10.00 | 8,552 | 85,520 | 88,980 | Nov 10 |
| Glessner Coleen | EVP, Quality & Ethics, and CPL | Oct 07 '25 | Sale | 10.00 | 30,608 | 306,080 | 144,319 | Oct 16 |
| Zoon Kathryn C | Director | Aug 15 '25 | Sale | 8.87 | 7,086 | 62,853 | 71,799 | Aug 18 |
| DeGolyer Donald W | Director | Aug 12 '25 | Sale | 8.65 | 7,844 | 67,831 | 137,659 | Aug 13 |